Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases

This study aims to conduct a prospective, multicenter, umbrella clinical study to compare the abscopal effects of different radiotherapy fractionation patterns combined with Benmelstobart, and to explore an efficient and low-toxic treatment strategy for non-small cell lung cancer (NSCLC) with multiple metastases. The main objective is to explore and compare the control rates of abscopal lesions in NSCLC patients with multiple metastases when different radiotherapy fractionation patterns are combined with Benmelstobart.

Trial Details

NCT ID

NCT06953843

Phase

PHASE2

Sponsor

Xinqiao Hospital of Chongqing

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Benmelstobart combined with chemotherapy
Benmelstobart combined with Bevacizumab and chemotherapy

Locations (sample)

Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

Patient must meet all of the following inclusion criteria to be enrolled in this study:
Non-small cell lung cancer confirmed by pathological histology.
More than 3 metastatic lesions.
No brain metastases or stable lesions.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →